pyrazines has been researched along with Cholera Infantum in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.41) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 10 (37.04) | 29.6817 |
| 2010's | 12 (44.44) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Aurran-Schleinitz, T; Chen, DY; Cheson, BD; D'Sa, S; Forconi, F; Frigault, MM; Furman, RR; Greenwald, D; Hamdy, A; Iyengar, S; Izumi, R; Kastritis, E; Kersten, MJ; Kothari, J; Lee, SK; McCarthy, H; Minnema, MC; Mittag, D; Owen, RG; Patel, P; Rule, S; Thomas, SK; Tournilhac, O; Walter, H; Wei, H; Zinzani, PL | 1 |
| Lim, KJC; Tam, CS | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Pantani, L; Perrone, G; Pezzi, A; Rocchi, S; Tacchetti, P; Tosi, P; Zamagni, E; Zannetti, BA | 1 |
| Eom, HS; Jo, DY; Jun, HJ; Kim, JS; Kim, K; Kim, KH; Kim, SH; Kim, SJ; Kim, YS; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Min, CK; Moon, JH; Mun, YC; Park, SK; Ryoo, HM; Suh, C; Voelter, V; Yoon, SS | 1 |
| Bartlett, NL; Beck, JT; Cherfi, A; Cheung, W; Collins, RH; Fan, J; Fanning, SR; Goy, A; Johnston, PB; Kaminski, MS; Kaya, H; Klimovsky, J; Lister, J; O'Connor, OA; Popplewell, LL; Robeva, A; Tuscano, JM; Wang, M; Winter, JN | 1 |
| Cavalli, M; Chiarenza, A; Conticello, C; Cunsolo, R; Di Raimondo, C; Di Raimondo, F; Palumbo, GA; Romano, A; Vetro, C | 1 |
| de Waal, TT; Gorter, MH; Tascilar, M | 1 |
| Burness, CB; Duggan, ST; Keam, SJ | 1 |
| Berdel, WE; Einsele, H; Gann, CN; Knop, S; Kropff, M; Liebisch, P; Wand, H; Weisel, K | 1 |
| Butcher, BE; Cannell, P; Horvath, N; Mikhael, JR; Prince, HM; Quach, H | 1 |
| Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P | 1 |
| Mateos, MV | 1 |
| Fujita, Y; Fukushima, T; Iwao, H; Masaki, Y; Miki, M; Motoo, Y; Nakajima, A; Nakajima, H; Nakamura, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Argnani, L; Baccarani, M; Ballerini, F; Broccoli, A; Casadei, B; Derenzini, E; Fabbri, A; Gandolfi, L; Guarini, A; Merla, E; Pavone, V; Pellegrini, C; Puccini, B; Quintini, G; Quirini, F; Stefoni, V; Vigliotti, ML; Zinzani, PL | 1 |
| Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A | 1 |
| Chen, Q; Du, XL | 1 |
| Colson, K; Doss, DS; Swift, R; Tariman, J; Thomas, TE | 1 |
| Bay, JO; Blay, JY; Rixe, O; Spano, JP | 1 |
| Anagnostopoulos, A; Bitsaktsis, A; Castritis, E; Dimopoulos, MA; Kyrtsonis, MC; Pangalis, GA | 1 |
| Atkins, JN; Bajorin, DF; Halabi, S; Himelstein, AL; Hohl, RJ; Millard, F; Rosenberg, JE; Sanford, BL; Small, EJ | 1 |
| Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Esseltine, DL; Fuertes, M; García-Laraña, J; Garcia-Sanchez, P; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H | 1 |
| Alberti, D; Binger, K; Eickhoff, J; Geiger, P; Heideman, J; Kolesar, J; LoConte, NK; Marnocha, R; Thomas, JP; Utecht, K; Wilding, G | 1 |
| Carey, LA; Collichio, F; Collins, J; Dees, EC; Esseltine, D; Ivanova, A; Lindley, CM; O'Neil, BH; Orlowski, RZ; Riordan, WJ | 1 |
| Lachowicz, D; Siekierzyńska, A; Styszewska, H | 1 |
| Alcazar, JM; Diaz, VP; Jarillo, MD; Millet, VG; Rodicio, JL; Ruilope, L | 1 |
| Ames, MM; Dhodapkar, MV; Reid, JM; Richardson, RL | 1 |
| Bolanowska-Higdon, W; Creaven, PJ; Hitt, S; Lawrence, D; Murphy, M; Pendyala, L; Schwartz, G; Zdanowicz, J | 1 |
6 review(s) available for pyrazines and Cholera Infantum
| Article | Year |
|---|---|
Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Atrial Fibrillation; Benzamides; Central Nervous System Diseases; Clinical Trials as Topic; Febrile Neutropenia; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Humans; Multicenter Studies as Topic; Myeloid Differentiation Factor 88; Neoplasm Proteins; NF-kappa B; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Receptors, CXCR4; Recurrence; Salvage Therapy; Signal Transduction; Treatment Outcome; Waldenstrom Macroglobulinemia | 2020 |
Selexipag: A Review in Pulmonary Arterial Hypertension.
Topics: Acetamides; Antihypertensive Agents; Clinical Trials as Topic; Gastrointestinal Diseases; Headache; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
Management of treatment-related adverse events in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Venous Thromboembolism | 2010 |
Recent advancements of bortezomib in acute lymphocytic leukemia treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Thrombocytopenia; Valproic Acid | 2013 |
Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
Topics: Anemia; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Monitoring; Gastrointestinal Diseases; Humans; Hypotension; Multiple Myeloma; Neutropenia; Nurse's Role; Oncology Nursing; Patient Care Planning; Patient Education as Topic; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Quality of Life; Thrombocytopenia; Water-Electrolyte Imbalance | 2004 |
Proteasome inhibition: a new approach for the treatment of malignancies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Primates; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rodentia | 2005 |
10 trial(s) available for pyrazines and Cholera Infantum
| Article | Year |
|---|---|
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Neoplasm Proteins; Neutropenia; Pain; Protein Kinase Inhibitors; Pyrazines; Quality of Life; Recurrence; Respiratory Tract Infections; Salvage Therapy; Treatment Outcome; Waldenstrom Macroglobulinemia | 2020 |
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Pain; Pneumonia; Pyrazines; Salvage Therapy; Sirolimus; Treatment Outcome | 2014 |
DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Remission Induction | 2009 |
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Europe; Female; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Treatment Outcome | 2013 |
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Transitional Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Salvage Therapy; Treatment Failure; Urologic Neoplasms | 2008 |
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Survival Analysis | 2008 |
A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasms; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Salvage Therapy; Treatment Outcome; Ubiquitination | 2008 |
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasms; Polyethylene Glycols; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Treatment Outcome | 2008 |
Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.
Topics: Adult; Aged; Antineoplastic Agents; Drug Tolerance; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Pyrazines | 1994 |
Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity.
Topics: Acetylcysteine; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Pyrazines; Reference Values; Risk Assessment; Smoking; Thiones; Thiophenes | 2001 |
11 other study(ies) available for pyrazines and Cholera Infantum
| Article | Year |
|---|---|
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 2014 |
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Korea; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2014 |
[Gastrointestinal amyloidosis in a patient with multiple myeloma].
Topics: Abdominal Pain; Amyloidosis; Biopsy; Boronic Acids; Bortezomib; Colon, Sigmoid; Dexamethasone; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2014 |
Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Australia; Boronic Acids; Bortezomib; Cohort Studies; Female; Gastrointestinal Diseases; Humans; International Cooperation; Male; Middle Aged; Multiple Myeloma; New Zealand; Pyrazines; Recurrence; Treatment Outcome | 2009 |
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Gastrointestinal Diseases; Glomerular Filtration Rate; Hematologic Diseases; Humans; Italy; Kidney Diseases; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide | 2010 |
Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2011 |
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Off-Label Use; Peripheral Nervous System Diseases; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Rituximab; Signal Transduction; Transplantation, Autologous; Treatment Outcome | 2013 |
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Waldenstrom Macroglobulinemia | 2005 |
[Morphazinamide--clinical tolerance and side effects].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Ethionamide; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Pyrazinamide; Pyrazines; Tuberculosis, Pulmonary | 1967 |
A fixed combination of hydrochlorothiazide and amiloride for the treatment of essential hypertension.
Topics: Adolescent; Adult; Aged; Amiloride; Blood Chemical Analysis; Blood Pressure; Body Weight; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Hydrochlorothiazide; Hyperglycemia; Hypertension; Male; Middle Aged; Pyrazines; Uric Acid | 1980 |